Cargando…

Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes

BACKGROUND: Patients with multiple sclerosis (MS) on some disease modifying therapies (DMTs), particularly anti-CD20 and sphingosine-1-phosphate (S1P) modulators, are at increased risk of severe Coronavirus Disease 19 (COVID-19) and death. COVID-19 vaccinations are effective in preventing infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holroyd, Kathryn B., Healy, Brian C., Conway, Sarah, Houtchens, Maria, Bakshi, Rohit, Bhattacharyya, Shamik, Bose, Gauruv, Galetta, Kristin, Kaplan, Tamara, Severson, Christopher, Singhal, Tarun, Stazzone, Lynn, Zurawski, Jonathan, Polgar-Turcsanyi, Mariann, Saxena, Shrishti, Paul, Anu, Glanz, Bonnie I., Weiner, Howard L., Chitnis, Tanuja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330583/ https://www.ncbi.nlm.nih.gov/pubmed/35952457 http://dx.doi.org/10.1016/j.msard.2022.104079

Ejemplares similares

Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine
por: Conway, Sarah, et al.
Publicado: (2023)

Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders
por: Conway, Sarah E., et al.
Publicado: (2022)

Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity
por: Bose, Gauruv, et al.
Publicado: (2023)

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
por: Sotiropoulos, Marinos G, et al.
Publicado: (2021)

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
por: Barro, Christian, et al.
Publicado: (2022)

Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
por: Lokhande, Hrishikesh, et al.
Publicado: (2022)

Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models
por: Chua, Alicia S., et al.
Publicado: (2015)

An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2
por: Bakshi, Rohit, et al.
Publicado: (2014)

Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis
por: Galetta, Kristin, et al.
Publicado: (2021)

Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study
por: Zhao, Yijun, et al.
Publicado: (2020)

Author Correction: Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study
por: Zhao, Yijun, et al.
Publicado: (2020)

MRI activity in MS and completed pregnancy: Data from a tertiary academic center
por: Houtchens, Maria, et al.
Publicado: (2020)

The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2021)

Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis
por: Bose, Gauruv, et al.
Publicado: (2021)

The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis
por: Hemond, Christopher C., et al.
Publicado: (2019)

Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis
por: Rosso, Mattia, et al.
Publicado: (2020)

No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50
por: Bove, Riley, et al.
Publicado: (2013)

Clinical and radiologic outcomes in two patients with multiple sclerosis treated with tocilizumab for COVID-19
por: Holroyd, Kathryn B., et al.
Publicado: (2022)

Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2013)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis
por: Dastagir, Akram, et al.
Publicado: (2018)

Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
por: Healy, Brian C, et al.
Publicado: (2021)

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
por: Tauhid, Shahamat, et al.
Publicado: (2015)

Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2017)

Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients
por: Rosso, Mattia, et al.
Publicado: (2019)

Effect of vitamin D on MS activity by disease-modifying therapy class
por: Rotstein, Dalia L., et al.
Publicado: (2015)

History of fatigue in multiple sclerosis is associated with grey matter atrophy
por: Palotai, Miklos, et al.
Publicado: (2019)

Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseases
por: Saxena, Shrishti, et al.
Publicado: (2020)

Validation of Two Kinetic Assays for the Quantification of Endotoxin in Human Serum
por: Barro, Christian, et al.
Publicado: (2021)

Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis
por: Rissanen, Eero, et al.
Publicado: (2022)

Exploration of machine learning techniques in predicting multiple sclerosis disease course
por: Zhao, Yijun, et al.
Publicado: (2017)

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
por: Regev, Keren, et al.
Publicado: (2016)

Risk attitudes and risk perceptions in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2016)

Evaluation of an Online Platform for Multiple Sclerosis Research: Patient Description, Validation of Severity Scale, and Exploration of BMI Effects on Disease Course
por: Bove, Riley, et al.
Publicado: (2013)

COVID-19 mRNA vaccination leading to CNS inflammation: a case series
por: Khayat-Khoei, Mahsa, et al.
Publicado: (2021)

Blood neurofilament light: a critical review of its application to neurologic disease
por: Barro, Christian, et al.
Publicado: (2020)

The Effect of Fingolimod on Conversion of Acute Gadolinium‐Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis
por: Oommen, Vinit V., et al.
Publicado: (2015)

microRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance
por: Fujiwara, Mai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_27p524egcq01uf7f776sl7svn3